Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence

• Alcon Vivity Registry has continued to achieve excellent results with the AcrySof Vivity, AcrySof Vivity Toric and PCIOL.⁺Wavefront shaping technology
• New registry data, including rates of vision disturbances, will be presented by world-renowned surgeons at #ESCRS2023.^1,2
• After surgery, the registry tracked 900+ patients with cataracts. This included those who had mild comorbidities.

GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity^®The Registry Study monitored the real-world experiences of patients for up to twelve months after cataract surgery using either AcrySof or AcrySof Implants.^®The IQ Vivity^®AcrySof^®The IQ Vivity^® Toric presbyopia-correcting intraocular lens (PCIOL). More than 900 patients with cataracts showed sustained clinical performance and high patient satisfaction, as well as reduced dependency on spectacles. AcrySof was also found to be more effective than other lenses.^®The IQ Vivity^®The technique can be successfully used in many different patients and provides surgeons with more treatment options.

“Since its introduction, AcrySof^®The IQ Vivity^® has been a disruptive technology—and an innovation we are very proud of as a company. Vivity^®This is the first of its kind non-diffractive IOL with extended depth focus built using our proprietary XWAVE technology.^TM technology, which stretches and shifts light without splitting it,” said Sunil Vasanth, VP, Europe Surgical Franchise, Alcon. “Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”

The Vivity^®Registration Study³This was an open-label non-interventional, multicentre registry, which included 41 sites across eight countries. These were Australia, Belgium Germany New Zealand the Netherlands Portugal Spain the United Kingdom. Researchers found that:³

• The patients who reported having no difficulties with sight in daily life were three-quarters.^∞
• The majority of patients (92%) are satisfied with the quality of their vision^‡
• Over 91% reported that they did not see any halos, stars or glares.^†(common visual disorders that result from splitting light within a diffractive IOL).
• The binocular distance was excellent and the uncorrected Snellen values were 20/20.
• More than 78% and 88% of patients reported they no longer needed to use glasses to see at arm’s length and far away, respectively^§

This data and other results will be discussed with 11 world-renowned doctors at the 41^{The st}The European Society of Cataract and Refractive Surgeons Congress is currently taking place in Vienna, Austria. Visit MyAlconatESCRS.com to see a comprehensive overview of the relevant abstracts.

AcrySof^®The IQ Vivity^®, a non-diffractive IOL, uses Alcon’s proprietary Wavefront-Shaping X-WAVE^TMTechnology, an optical principle of the next generation that shifts and stretches light without dividing it.²It meets a medical need for excellent near, distance and intermediate vision, e.g. to perform close-up activities like using mobile devices, while minimizing visual disturbances.²

Vision is at the top of people’s minds as they get older—and surgeons can make a difference

A new Global Alcon Survey shows that vision is tied with mobility for the second-most important ageing quality (83%). Only memory scored higher, at 84%.^4,*Vision is the main concern of people with cataracts when they are aging. In the survey, 81% patients with PCIOLs reported improvement in their quality of living after surgery. The survey also found that 69% of people, even those without cataracts, said they would be liberated if their glasses were removed. 3 out of 4 people with cataracts awaiting surgery would pay for an eyeglass lens to eliminate the need for them.⁴

The power of vision is a key factor in helping people to age well. AcrySof^®The IQ Vivity^®Can help meet the demands of patients and their expectations in relation to performance, life quality and independence from spectacles.

AcrySof^®The IQ Vivity^®AcrySof^®The IQ Vivity^®Please contact your Alcon Rep if you have any questions regarding Toric’s availability on your local market. Please refer to relevant products DFU or Operator’s manuals for complete list of indications, contraindications and warnings.

The content of this page is only intended for Healthcare Professionals. Note that the promotion of Medical Devices by non-HCPs is subject to local regulations and rules.

What is AcrySof?^®The IQ Vivity^® IOL

Non-diffractive AcrySof^®The IQ Vivity^®Model DFT015 (also called AcrySof Extended Vision Posterior Cell Intraocular Lens)^®The IQ Vivity^®IOL (foldable intraocular lenses) are UV-absorbing, blue-light filtering and foldable. Comparing this IOL to monofocal IOLs, it provides greater vision range from far to close without the risk of visual disturbance.

The IOL can have side effects. Complications of IOL surgery can range from temporary side effects to more serious ones. Prior illnesses and disorders, such as chronic infections in the eyes or eyelids or diabetes, may increase a patient’s risk for complications. The temporary surgical complications can include but not be limited to reactions to medication such as mild allergy, irritation, or redness of the eye. They may also cause sensitivity to lights, swelling, corneal inflammation (or swelling of the cornea), iris problems, IOL cell growth, and increased eye pressure. After the initial IOL implantation, there is a slight risk that you may need further surgery (such as an IOL replaced by another one or surgery for improved vision).

Alcon

Alcon makes people brilliantly see. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. More than 260,000,000 people live with eye conditions such as cataracts and glaucoma in more 140 countries. We have more than 25.000 associates who improve quality of life by enhancing access to high-quality eye care, partnering with Eye Care Professionals or developing innovative products. Visit www.alcon.com to learn more.

Referrals

1. AcrySof^®The IQ Vivity^®Extended Vision IOL DFU.
2. Bala et al. Multicountry clinical outcomes of a new nondiffractive presbyopia-correcting IOL. J Cataract Refract Surg 2022; 48:136–143.
3. Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at European Society of Cataract and Refractive Surgery Annual Meeting, 8-12 September 2023, Vienna, Austria.
4. Alcon Cataract Survey [REF-21516].

⁺Presbyopia correcting intraocular lens

^∞CATQUEST9SF was asked to patients: Is your poor vision causing you difficulty in performing daily activities? What is the extent of your difficulty?

^‡Catquest 9SF Questionnaire was used to evaluate subject satisfaction. Statistic refers to ‘very’ or ‘fairly’ satisfied.

^†Asking open questions, without prompting about the visual experience was used to evaluate disturbances.

^§How many times did you wear your eyeglasses in the past seven days to be able to see clearly?

*The Alcon Eye Cataract survey was conducted between March and April 2023 in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea and the United States, and set out to evaluate vision and cataract insights among the world’s rapidly aging population. The total number of participants in the survey was 7,331. This included 1,826 people who were diagnosed within the past five years and had undergone cataract surgery, as well as 5,505 who hadn’t been diagnosed and had not had surgery.

Join us on Facebook

Facebook
You can find us on LinkedIn.
X

Contacts

Investor Relations
Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Media Relations
Cara Jones-Faye

+ 41 79 93 3811 (Geneva)

Cara.Jones_Faye@Alcon.com